DK1173484T3 - Behandling af fibrose ved antagonisme mellem IL-13 og IL-13-receptorkæder - Google Patents

Behandling af fibrose ved antagonisme mellem IL-13 og IL-13-receptorkæder

Info

Publication number
DK1173484T3
DK1173484T3 DK00928591.7T DK00928591T DK1173484T3 DK 1173484 T3 DK1173484 T3 DK 1173484T3 DK 00928591 T DK00928591 T DK 00928591T DK 1173484 T3 DK1173484 T3 DK 1173484T3
Authority
DK
Denmark
Prior art keywords
fibrosis
antagonism
treatment
receptor chains
receptor
Prior art date
Application number
DK00928591.7T
Other languages
English (en)
Inventor
Thomas A Wynn
Monica G Chiaramonte
Debra Donaldson
Lori Fitz
Tamlyn Neben
Clive Wood
Mary Collins
Matthew J Whitters
Original Assignee
Genetics Inst Llc
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23164976&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1173484(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst Llc, Us Gov Health & Human Serv filed Critical Genetics Inst Llc
Application granted granted Critical
Publication of DK1173484T3 publication Critical patent/DK1173484T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
DK00928591.7T 1999-04-28 2000-04-28 Behandling af fibrose ved antagonisme mellem IL-13 og IL-13-receptorkæder DK1173484T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/301,808 US6664227B1 (en) 1996-03-01 1999-04-28 Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
PCT/US2000/011612 WO2000064944A1 (en) 1999-04-28 2000-04-28 Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains

Publications (1)

Publication Number Publication Date
DK1173484T3 true DK1173484T3 (da) 2011-10-03

Family

ID=23164976

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00928591.7T DK1173484T3 (da) 1999-04-28 2000-04-28 Behandling af fibrose ved antagonisme mellem IL-13 og IL-13-receptorkæder

Country Status (16)

Country Link
US (2) US6664227B1 (da)
EP (2) EP1173484B1 (da)
JP (3) JP4988988B2 (da)
KR (1) KR100862931B1 (da)
CN (1) CN1348465A (da)
AT (1) ATE515513T1 (da)
AU (1) AU780991B2 (da)
BR (1) BR0010061A (da)
CA (1) CA2370306C (da)
DK (1) DK1173484T3 (da)
HU (1) HU230582B1 (da)
IL (2) IL146082A0 (da)
MX (1) MXPA01011023A (da)
NZ (1) NZ515464A (da)
PT (1) PT1173484E (da)
WO (1) WO2000064944A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
PT1141286E (pt) 1998-12-14 2007-01-31 Genetics Inst Llc Cadeia de receptores de citocina
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
EP1455833A1 (en) * 2001-12-04 2004-09-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Chimeric molecule for the treatment of th2-like cytokine mediated disorders
WO2003086451A1 (en) * 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
EP1552462B1 (en) * 2002-06-14 2011-03-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods of treating and preventing colitis involving il-13 and nk-t cells
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
PT1703893E (pt) 2003-12-23 2012-06-01 Genentech Inc Novos anticorpos anti-il 13 e as respectivas utilizações
EP1713441A2 (en) * 2004-02-12 2006-10-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
PT1734970E (pt) 2004-03-12 2015-03-11 Intercept Pharmaceuticals Inc Tratamento de fibrose utilizando ligandos de rfx
AU2005250478A1 (en) * 2004-06-04 2005-12-15 Wyeth Inhibitors of REGIII proteins as asthma therapeutics
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
WO2006124451A2 (en) * 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
JP2010514409A (ja) * 2006-06-21 2010-05-06 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ヒトの癌における鑑別式サイトカイン発現
WO2008003514A2 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
GB0615881D0 (en) * 2006-08-10 2006-09-20 Univ Southampton Novel peptide for treatment of asthma
AU2007351514B2 (en) 2006-09-08 2013-02-21 Abbvie Inc. Interleukin -13 binding proteins
MX2009006457A (es) * 2006-12-15 2009-08-25 Centocor Ortho Biotech Inc Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13.
RU2009140134A (ru) * 2007-04-23 2011-05-27 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CN101318013B (zh) * 2008-07-17 2013-04-10 四川大学 Il-4在制备治疗慢性肝纤维化的药物组合物中的用途
US8399630B2 (en) * 2008-08-20 2013-03-19 Centocor Ortho Biotech Inc. Engineered anti-IL-13 antibodies, compositions, methods and uses
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
TWI700093B (zh) 2011-03-16 2020-08-01 法商賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
PT2953948T (pt) 2013-02-07 2017-12-12 Scifluor Life Sciences Inc Antagonistas de integrina fluorada
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
NZ718144A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
WO2016044707A1 (en) 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
WO2016077675A1 (en) * 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
JP2018510139A (ja) 2015-02-19 2018-04-12 サイフルーア ライフ サイエンシズ インコーポレイテッド フッ化テトラヒドロナフチリジニルノナン酸誘導体およびその使用法
US9572801B2 (en) 2015-04-30 2017-02-21 Scifluor Life Sciences, Inc. Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
CN105052892A (zh) * 2015-07-20 2015-11-18 山东省齐鲁干细胞工程有限公司 一种无dmso的冷冻保护剂与冷冻保存卵巢的方法
US20190086392A1 (en) 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
WO2017189828A1 (en) 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
CN113101364B (zh) 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用
EP4165066A1 (en) * 2020-06-12 2023-04-19 Beijing Vdjbio Co., Ltd. Fusion polypeptide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
WO1994004680A1 (en) 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
NZ292124A (en) 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
WO1997033913A1 (en) 1996-03-13 1997-09-18 Zymogenetics, Inc. Cytokine-receptor expressed in testis cells
AU6175696A (en) 1996-06-12 1998-01-07 Human Genome Sciences, Inc. Hr-1 receptor
EP0812913A3 (en) 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules

Also Published As

Publication number Publication date
HUP0200862A2 (hu) 2002-07-29
ATE515513T1 (de) 2011-07-15
JP2011078432A (ja) 2011-04-21
AU780991B2 (en) 2005-04-28
HUP0200862A3 (en) 2004-11-29
US6664227B1 (en) 2003-12-16
CN1348465A (zh) 2002-05-08
US7282206B2 (en) 2007-10-16
WO2000064944A1 (en) 2000-11-02
EP1173484B1 (en) 2011-07-06
KR20020026426A (ko) 2002-04-10
JP2014087345A (ja) 2014-05-15
BR0010061A (pt) 2003-02-25
JP4988988B2 (ja) 2012-08-01
EP1173484A1 (en) 2002-01-23
EP1173484A4 (en) 2003-05-21
IL146082A (en) 2014-08-31
AU4680500A (en) 2000-11-10
CA2370306C (en) 2014-06-17
HU230582B1 (hu) 2017-01-30
EP2123674A1 (en) 2009-11-25
NZ515464A (en) 2004-02-27
MXPA01011023A (es) 2002-05-06
JP2003527311A (ja) 2003-09-16
IL146082A0 (en) 2002-07-25
US20050096268A1 (en) 2005-05-05
CA2370306A1 (en) 2000-11-02
PT1173484E (pt) 2011-09-29
KR100862931B1 (ko) 2008-10-13

Similar Documents

Publication Publication Date Title
DK1173484T3 (da) Behandling af fibrose ved antagonisme mellem IL-13 og IL-13-receptorkæder
SE9900100D0 (sv) New compounds
DK1616869T3 (da) Substituerede porphyriner og deres terapeutiske anvendelse
AU7316601A (en) Methods for treating inflammation-mediated conditions of the eye
IT1313574B1 (it) Rete correttiva per tessuti corporei.
PT1187918E (pt) Antagonistas de tek
NO20015156D0 (no) 5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse
CY1108041T1 (el) Αναστολεις της rho-κινασης
BE2010C030I2 (da)
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
HK1057363A1 (en) Ccr5 antagonists useful for treating aids.
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
DE69936285D1 (de) INDOLOi2,1-BöQUINAZOLIN-6,12-DIONE ANTIMALARIA DERIVATE UND METHODEN ZUR BEHANDLUNG VON MALARIA
NO20012228L (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
GC0000155A (en) 6-Hydroxy-indazole derivatives for treating glaucoma.
EP1409015A4 (en) METHODS OF TREATING OR PREVENTING SKIN DISORDERS USING CD2 BINDING AGENTS
CA2474510A1 (en) Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
EP1267903A4 (en) METHODS OF TREATING GLAUCOMA
AU2003249181A8 (en) Methods for treating or preventing ischemic injury
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
NO20002456D0 (no) Anordning til behandling av vann
EP1419236A4 (en) METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
DK0916670T3 (da) Pyrrolo[3,2-b]pyridiner og deres anvendelse som 5-HT1f-agonister
NZ511997A (en) Isonipecotamides for the treatment of integrin-mediated disorders